Can-Fite BioPharma Ltd. (CANF)

Market Cap	6.99M -56.2%
Revenue (ttm)	405,000 -39.9%
Net Income	-9.83M
EPS	-5.97
Shares Out	4.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,928
Open	3.340
Previous Close	3.350
Day's Range	3.160 - 3.340
52-Week Range	2.830 - 23.400
Beta	0.03
Analysts	Strong Buy
Price Target	6.00 (+85.19%)
Earnings Date	Mar 26, 2026

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 5
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CANF
• Website: https://www.canfite.com

Financial Performance

In 2025, Can-Fite BioPharma's revenue was $405,000, a decrease of -39.91% compared to the previous year's $674,000. Losses were -$9.83 million, 24.7% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for CANF stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 85.19% from the latest price.

Price Target

$6.0

(85.19% upside)

Analyst Consensus: Strong Buy